Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

2.

Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.

Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D.

Ann Intern Med. 2008 May 6;148(9):671-9. Review.

PMID:
18458280
3.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.

J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11.

4.

Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.

Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C.

Radiology. 2007 Aug;244(2):381-8.

PMID:
17641362
5.

Clinical practice. Management of an inherited predisposition to breast cancer.

Robson M, Offit K.

N Engl J Med. 2007 Jul 12;357(2):154-62. Review. No abstract available.

PMID:
17625127
6.

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA; American Cancer Society Breast Cancer Advisory Group.

CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. Erratum in: CA Cancer J Clin. 2007 May-Jun;57(3):185.

PMID:
17392385
7.

Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.

Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R; IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group.

Cancer. 2007 May 1;109(9):1784-90.

8.

Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

Evers B, Jonkers J.

Oncogene. 2006 Sep 25;25(43):5885-97. Review.

PMID:
16998503
9.

Clinical management of BRCA1 and BRCA2 mutation carriers.

Domchek SM, Weber BL.

Oncogene. 2006 Sep 25;25(43):5825-31. Review.

PMID:
16998496
10.

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

JAMA. 2006 Jul 12;296(2):185-92.

11.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.

PMID:
16720823
12.

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR.

Lancet Oncol. 2006 Mar;7(3):223-9.

PMID:
16510331
13.

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.

Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2006 May 1;118(9):2281-4.

14.

Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.

Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH.

J Clin Oncol. 2005 Dec 1;23(34):8629-35.

PMID:
16314625
15.

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA.

J Clin Oncol. 2005 Oct 20;23(30):7491-6.

PMID:
16234515
16.

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium.

Clin Cancer Res. 2005 Jul 15;11(14):5175-80.

17.

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM; MARIBS study group.

Lancet. 2005 May 21-27;365(9473):1769-78. Erratum in: Lancet. 2005 May 28-Jun 3;365(9474):1848.

PMID:
15910949
18.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
19.

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group.

N Engl J Med. 2004 Jul 29;351(5):427-37.

20.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA.

J Clin Oncol. 2004 Jun 15;22(12):2328-35.

PMID:
15197194

Supplemental Content

Support Center